Semaglutide 2.4 mg (a GLP-1) has demonstrated an average weight loss of 15% weight loss over 68 weeks (7) and now includes an indication for the prevention of major adverse cardiovascular events in people with overweight or obesity without diabetes (8). Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.